ArticleFrontiers in medicine2025
Predictive model for coronavirus disease 2019 severity based on blood biomarkers: a retrospective study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence Integrated Smart Medical Imaging Lab Framework for Enhanced Diagnosis and Treatment of Pandemic-Prone Diseases.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a clinical prediction model for assessing the severity of coronavirus disease 2019 (COVID-19) using blood biomarkers, aiming to support clinical decision-making and treatment guidance. Methods: A retrospective cohort study was conducted at Beijing Shijitan Hospital on January 5, 2023, including SARS-CoV-2 positive patients with initial chest CT-detected from outpatient and emergency departments. Data on demographics, symptoms, and blood biomarkers were collected. Patients were categorized into non-severe (mild and moderate) and severe (severe and critical) groups based on clinical symptoms and disease progression. Outpatient data served as the training set for modeling and validation using logistic regression and 10-fold cross validation. Emergency department data functioned as an independent external validation set to test the model's generalizability. Results: The study included 1,007 patients, with 778 in the training set and 229 in the validation set. The C-reactive protein (CRP), neutrophil count (NE), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) were significantly higher in the severe COVID-19 group, while lymphocyte count (LY) and eosinophil count (EO) were significantly lower in the non-severe group ( Conclusion: The predictive model, informed by blood biomarkers, successfully discriminates against COVID-19 patients at higher risk for severe outcomes, offering a valuable tool for clinical management and resource optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.